CelLynx 10-Q 5 Nov 13 2013 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Mar. 31, 2013	Sep. 30, 2013
Document And Entity Information	'	'
Entity Registrant Name	'CelLynx Group, Inc.	'
Entity Central Index Key	'0001067286	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--09-30	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	2,048,498,001
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash	$14	($284)
TOTAL CURRENT ASSETS	14	-284
EQUIPMENT, net	608	1,359
INTANGIBLE ASSETS, net	48,474	48,737
TOTAL ASSETS	49,096	49,812
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses	2,104,620	1,890,211
Accrued interest	164,672	69,346
Accrued derivative liabilities	2,420,225	1,487,568
Line of credit	765,724	580,473
Promissory notes	397,956	390,488
TOTAL CURRENT LIABILITIES	5,853,197	4,418,086
TOTAL LIABILITIES	5,853,197	4,418,086
STOCKHOLDERS' DEFICIT:	'	'
Series A preferred stock, $0.001 par value; 100,000,000 shares authorized; nil shares issued and outstanding	'	'
Common stock, $0.001 par value, 2,000,000,000 shares authorized; 1,601,498,001 and 1,457,498,001 shares issued and outstanding as of March 31, 2013 and September 30, 2012 respectively.	1,601,497	1,457,498
Additional paid-in capital	13,044,849	13,170,581
Accumulated deficit	-18,650,447	-17,196,353
Treasury stock	-720,000	-450,000
Accumulated other comprehensive income	-1,080,000	-1,350,000
Total stockholders' deficit	-5,804,101	-4,368,274
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$49,096	$49,812

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock Par value (in Dollars per share)	$0.00	$0.00
Common stock, Shares authorized	2,000,000,000	2,000,000,000
Common stock, Shares issued	1,601,498,001	1,457,498,081
Common stock, Outstanding	1,601,498,001	1,457,498,081

Condensed_Consolidated_Stateme

Condensed Consolidated Statement of Operations (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Income Statement [Abstract]	'	'	'	'
Sales	'	'	'	'
Cost of Sales	'	'	'	'
Selling general and administrative expenses:	'	'	'	'
Amortization and depreciation	638	3,732	1,015	4,571
Bank charges and interest	88,179	51,291	112,635	92,131
Research & development	39,000	'	78,000	'
General and administrative expenses	154,988	214,377	268,201	368,667
Total operating expenses	282,804	269,400	459,851	465,369
(Loss) from operations	-282,804	-269,400	-459,851	-465,369
Other income (expense):	'	'	'	'
Change in fair value of derivative liability	-2,115,823	-5,621,028	-992,832	-5,595,012
Change in fair value of accrued warrant and option liability	8,170	'	8,217	2,718
Gain on settlement of debt	52,240	3,766	52,240	3,766
Amortization of debt discount	-21,258	'	-61,867	'
Gain on sale of intangible assets	'	1,482,563	'	1,485,513
Total Other income (expense)	-2,076,671	-4,134,699	-994,242	-4,103,015
Net loss	-2,359,475	-4,404,099	-1,454,094	-4,568,384
Basic (loss) per common share	($0.00)	($0.02)	($0.00)	($0.02)
Weighted average number of shares outstanding	1,561,498,081	211,946,779	1,521,629,229	267,598,489
Other comprehensive income	'	'	'	'
Unrealized gain on investment	180,000	'	270,000	'
Other comprehensive income	180,000	'	270,000	'
Comprehensive (loss)	($2,179,475)	($4,404,099)	($1,184,094)	($4,568,384)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Cash Flows (USD $)	6 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($1,454,094)	($4,568,384)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	1,015	4,571
Stock based compensation	'	79,618
Note payable issued for services	'	50,000
Change in fair value of derivative liability	992,832	5,595,012
Change in debt discount on convertible notes	61,867	92,131
Change in fair value of accrued warrant and option liability	-4,696	-2,718
Change in line of credit for services	90,000	'
Gain on sale of intangibles	'	-1,485,513
Gain on settlement of debt	-52,240	-3,766
Changes in operating assets and liabilities:	'	'
Change in other assets	'	20,090
Change in accounts payable and accrued expenses	220,891	119,921
Change in unpaid interest and penalties on notes payable	117,433	76,774
Net cash from (used in) operating activities	-26,992	-99,038
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Net cash used in investing activities	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of convertible notes	'	15,000
Proceeds from convertible line of credit	27,290	87,106
Net cash provided by financing activities	27,290	102,106
NET INCREASE IN CASH	298	3,068
CASH, BEGINNING OF PERIOD	-284	178
CASH, END OF PERIOD	14	3,246
Supplementary disclosure of Cash Flow Information	'	'
Cash paid for interest	'	'
NON-CASH INVESTING AND FINANCING ACTIVITIES	'	'
Conversion of notes payable to common stock	$14,400	$52,700

Organization_Going_Concern_and

Organization, Going Concern and Exiting Development Stage	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Organization, Going Concern and Exiting Development Stage	'
	Note 1 – Organization, Going Concern and Exiting Development Stage
	Organization and Line of Business
	CelLynx Group, Inc. (the “Company”), was incorporated under the laws of the State of Minnesota on April 1, 1998. The Company changed its name from NorPac Technologies, Inc. to Cellynx Group, Inc. on August 5, 2008.
	The Company developed and patented a technology for a line of cellular network infrastructure devices for use in the small office, home and mobile market places.   The products are being further developed and brought to market by 5BARz International Inc., a Company which acquired a 60% interest in that technology and also a 60% equity interest in Cellynx Group, Inc.
	On July 24, 2008, the Company entered into a Share Exchange Agreement, as amended, with CelLynx, Inc., a California corporation ("CelLynx- California"). Pursuant to the terms of that share exchange agreement, the CelLynx-California shareholders were to receive 77,970,956 shares of the Company’s common stock in exchange for 100%, or 61,983,580 shares, of CelLynx-California’s common stock. The Company issued to the CelLynx-California shareholders an aggregate of 32,454,922 shares of common stock and 45,516,034 shares of Series A Preferred Stock. The Series A Preferred Stock automatically converted into common stock on a one-to-one ratio upon the authorized capital stock of the Company being increased to include not less than 150,000,000 shares of common stock.
	On November 7, 2008, the Company amended the Articles of Incorporation to increase the number of authorized shares to 400,000,000 and converted the 45,516,034 shares of Series A Preferred Stock into 45,516,034 shares of the Company’s common stock.
	The exchange of shares with CelLynx-California was accounted for as a reverse acquisition under the purchase method of accounting because the shareholders of CelLynx-California obtained control of the Company. At the date of the reverse merger transaction, the net assets of the legal acquirer CelLynx Group, Inc. were $1,248,748. As a result of the reverse merger transactions described above, the historical financial statements presented are those of CelLynx-California, the operating entity. Each CelLynx-California shareholder received 1.2579292 shares of stock in the Company for each share of CelLynx- California capital stock. All shares and per-share information have been retroactively restated for all periods presented to reflect the reverse merger transaction.
	On October 27, 2008, the Board of Directors approved a change of the Company’s fiscal year end from June 30 to September 30 to correspond to the fiscal year of CelLynx-California. The fiscal year end change was effective for the year ended September 30, 2008.
	On March 23, 2012, the Company amended the Articles of Incorporation to increase the number of authorized shares to 1,000,000,000. On May 7, 2012 the Company amended the Articles of Incorporation to increase the number of authorized shares to 2,000,000,000 and on May 1, 2013 the Company amended the Articles of Incorporation to increase the number of authorized shares to 4,450,000,000.
	These financial statements reflect the financial position and results of operations for the Company and its wholly owned subsidiary Cellynx, Inc. for the six month period ended March 31, 2013.
	Going concern
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company has incurred losses for the period from October 1, 2012 through March 31, 2013 of $1,454,094. The Company has negative cash flows from operations for the six months ended March 31, 2013 of $26,992 and has an accumulated deficit of $18,650,447 at March 31, 2013. The Company has made no revenue to date. The Company is seeking additional sources of equity or debt financing, and there is no assurance these activities will be successful. These factors raise substantial doubt about the Company’s ability to continue as a going concern and the Company’s continued existence is dependent upon adequate additional financing being raised to develop its sales and marketing program for the sales of 5BARz product.
	The Company is in default on certain notes payable. Accordingly, any penalties and interest has been accrued as of March 31, 2013 (see Note 4 (d)).
	The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
	Exiting Development Stage
	The Company was in the development stage through June 30, 2009. In July 2009, the Company received the first 220 units of the Company’s cellular network extender, The Road Warrior, from its manufacturer. As of July 2009, the Company became fully operational and as such was no longer considered a development stage company. During the period that the Company was considered a development stage company, the Company incurred accumulated losses of approximately $10,948,625.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Summary of Significant Accounting Policies	'
	Note 2 – Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended March 31, 2013, are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2013. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on January 15, 2013 for the fiscal year ended September 30, 2012.
	The accompanying consolidated financial statements include the accounts of CelLynx Group, Inc., and its 100% wholly -owned subsidiary, CelLynx, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include impairment analysis for long lived assets, income taxes, litigation and valuation of derivative instruments. Actual results could differ from those estimates.
	Intangible Assets
	Acquired patents, licensing rights and trademarks are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees, and models and drawings required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated with applications that are not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident increase in the value of the patents are capitalized.
	Capitalized costs for patents are amortized on a straight-line basis over the remaining twenty-year legal life of each patent after the costs have been incurred. Once each patent or trademark is issued, capitalized costs are amortized on a straight-line basis over a period not to exceed 20 years and 10 years, respectively. The licensing right is amortized on a straight-line basis over a period of 10 years. Based on its review, the Company believes that as of March 31, 2013 and September 30, 2012, there was no significant impairment of its intangible assets
	Fair value of financial instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these instruments.
	Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:
		•	Level 1. Quoted prices in active markets for identical assets or liabilities.
		•	Level 2. Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.
		•	Level 3. Significant unobservable inputs that cannot be corroborated by market data.
	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the assets that are measured at fair value on a recurring basis.
			Consolidated			Quoted Prices in Active Markets for Identical Assets or Liabilities		Quoted Prices for Similar Assets or Liabilities in Active Markets		Significant
			Balance Sheet			(Level 1)		(Level 2)		Unobservable
										Inputs
										(Level 3)
	Derivative Liabilities:
	Conversion option liability		$	2,420,225		$	—	$	—	$	2,420,225
	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:
			31-Mar-13
	Beginning balance – October 1, 2012		$	1,487,568
	Change in fair value of derivative liabilities			992,832
	Write down of derivative liabilities on default of securities			(51,613	)
	Change in accounting treatment of option and warrant liability			(8,562	)
	Ending balance – March 31, 2013		$	2,420,225
	Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivate liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, which reports to the Chief Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department with support from the Company’s consultants and which are approved by the Chief Financial Officer.
	Level 3 financial liabilities consist of the derivative liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.
	As of March 31, 2013 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.
	Derivative instruments
	The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging”. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.
	Net loss per share
	The Company reports loss per share in accordance with the ASC Topic 260, “Earnings Per Share.”, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.  In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities were not included in the calculation of loss per common share for the three and six months ended March 31, 2013 or 2012 because their effect would be anti-dilutive.
	Stock Based Compensation
	The Company reports stock-based compensation under ASC 718 “Compensation – Stock Compensation”. ASC 718 requires all share-based payments to employees, including grants of employee stock options, warrants to be recognized in the consolidated financial statements based on their fair values. The Company accounts for equity instruments issued to non-employees as compensation in accordance with the provisions of ASC 718, which require that each such equity instrument be recorded at its fair value on the measurement date, which is typically the date the services are performed. The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The model includes subjective input assumptions that can materially affect the fair value estimates. The model was developed for use in estimating the fair value of traded options or warrants. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or options granted.
	Reclassifications
	Certain reclassifications have been made in the financial statements at March 31, 2012 and for the three and six months then ended to conform to the March 31, 2013 presentation. The reclassifications had no effect on net loss.
	Recent accounting pronouncements
	In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment."  This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this guidance did not have a material effect on the condensed consolidated financial statements.
	FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of March 31, 2013 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2013 or 2012, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

Intangible_Assets

Intangible Assets	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Intangible Assets	'
	Note 3 – Intangible Assets
	The Company incurred legal costs in acquiring patent and trademark rights. These costs are projected to generate future positive cash flows in the near term and have been capitalized to intangible assets in the period incurred. Once each patent or trademark is issued, capitalized costs are amortized on a straight-line basis over a period not to exceed 20 years and 10 years, respectively. On March 29, 2012, the Company sold a 60% interest in their patents to 5BARz International Inc. The balances below reflect the residual balance at cost.
	Intangible assets consist of the following:
		31-Mar-13			30-Sep-12
	Patents	$	46,862		$	46,862
	Trademarks		4,995			4,995
	Licensing rights		4,214			4,214
			56,071			56,071
	Accumulated Amortization		(7,597	)		(7,334	)
	Intangibles, net	$	48,473		$	48,737
	During the six months ended March 31, 2013 and the year ended September 30, 2012 no amortization has been recorded on Patents. The other intangibles, comprised of trademarks and licensing rights have amortization of $263 recorded for the six months ended March 31, 2013 and $528 for the six months ended March 31, 2012.

Promissary_Note

Promissary Note	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Convertible Promissary Note	'
	Note 4 – Promissory Notes
	The Company has notes payable as follows;
									Converted to Common Stock
	Issue Date			Note Principal	Note		Accrued				Balance			Balance
					Terms		Interest				31-Mar-13			Sept. 30, 2012
	November. 10, 2007		$	262,356	(a)	$	56,583	$	—	$	318,939		$	313,677
	5-Apr-11			50,000	(b)		49,254		—		99,254			56,247
	5-Jan-12			50,000	(c)		36,324		—		86,324			52,498
	24-May-12			37,500	(d)		14,935		14,400		38,035			38,256
	12-Sep-12			12,500	(e)		7,576		—		20,076			12,549
											562,268			473,677
	Accrued interest										(164,672	)		(69,346	)
	Discount on notes										—			(18,869	)
	Notes payable		$	412,356		$	164,672	$	14,400	$	397,956		$	385,463
	(a)    On August 15, 2006, Cellynx, Inc. issued a secured promissory note (the “August 2006 Note”) for $250,000 to an unrelated entity “Holder”.  On November 10, 2007, the August 2006 Note was amended (the “Amended Note”).  The principal amount of the Amended Note is $262,356, is unsecured and bears interest at 4% per annum, computed on the basis of the actual number of days elapsed and a year of 365 days.  All unpaid principal, together with any then accrued but unpaid interest, shall be due and payable upon the earlier of (i) November 9, 2010 at the written request of the holder to the Company, or (ii) when, upon or after the occurrence of an event of default. The principal amount is convertible into 4.8% of the Company shares outstanding. At March 31, 2013, the Company recorded on its books principal and interest in the amount of $318,939.
	(b)   On April 5, 2011 (the April 5, 2011 Note), the Company entered into a Securities Purchase Agreement (the “SPA”) with a former Director of the Company. Pursuant to that Securities Purchase Agreement, the former director loaned to the Company the principal amount of $50,000. The Note bears interest at a rate of 8%, and was due on January 5, 2012. The “SPA” provides for the conversion of principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined by dividing the amount to be converted by the conversion price which is equal to 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion. On January 5, 2012 the Company did not repay the note as so was in default. Accordingly, the Company has accrued a default penalty of 50% of the note payable as well as default interest at 22% per annum from the date of the default and recorded a total of $99,254 on its books at March 31, 2013. The Company has the option to pay the amount due in cash or in shares as defined in the terms of the note agreement.
	(c)   Pursuant to the Note agreement dated January 5, 2012 (the “January 5, 2012 Note”), the Company received the principal amount of $50,000, by way of settlement of certain debts owed by the Company to Holder, a former officer of the Company. The Note bears interest at a rate of 8%, and was due on July 3, 2012. Prior to that date, Holder may convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined to be the amount obtained by dividing the amount to be converted by the conversion price which is the lesser of $0.0013 per share or 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion. On July 3, 2012 the note was not paid and accordingly the January 5, 2012 Note was in default. The Company has accrued a default penalty of 50% of the note payable as well as default interest at 22% per annum from the date of the default and recorded a total of $86,324 on its books at March 31, 2013. The Company has the option to pay the amount due in cash or in shares as defined in the terms of the note agreement.
	(d)   On May 24, 2012 and September 12, 2012, the Company received proceeds of $37,500 and $12,500, respectively, from an investor, pursuant to the terms of Securities Purchase Agreements and Convertible note agreements. The terms of these notes are such that subsequent to the prepayment date, which is six months after the issue date, if not paid, holder may convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined to be the variable conversion factor. The variable conversion factor is calculated by dividing the amount to be converted by the conversion price which is equal to 51% of the average of the three lowest closing bid prices of the Company’s common stock over the ten trading days prior to the date of the conversion. Holder is prohibited from converting amounts if principal and interest that would result in holder receiving shares, which when combined with shares of the Company’s common stock held, would result in investor holding more than 4.99% of the Company’s then- outstanding common stock.
		(e)	In December 2012 the Company’s parent, 5BARz International Inc. received a notice of default on notes entered into with the lender. Accordingly all notes to the lender have been recorded at the default amount at March 31, 2013 as the result of a cross default provision in the agreements. The Company has accrued a default penalty of 50% of the note payable as well as default interest at 22% per annum from the date of the default. The Company has the option to pay the amounts due in cash or in shares as defined in the terms of the notes agreements.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Stockholders' Equity	'
	Note 5 – Stockholder’s Equity
	During the six months ended March 31, 2013 and 2012, the Company issued 144,000,000 and 33,506,911 shares of common stock pursuant to the conversion of $14,400 and $34,500 principal of convertible notes payable.

Options

Options	6 Months Ended
	Mar. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Options	'
	Note 6 - Options
	At March 31, 2013, CelLynx Group Inc. has the following Options outstanding;
	The number and weighted average exercise prices of all options and warrants exercisable as of March 31, 2013, are as follows:
	Options Exercisable
		Options		Exercise price		Weighted average remaining contract life
	Opening – September 30, 2012		6,400,000	$	0.0008		0.4
	Granted		40,000,000		0.0002		2
	Expired		3,000,000		0.0008		0
	Outstanding – March 31, 2013		43,400,000	$	0.00025		1.87

Warrants

Warrants	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Warrants	'
	Note 7 - Warrants
	The following table summarizes the warrant activity to March 31, 2013:
		Number of		Weighted Average		Average Remaining
		Warrants		Exercise Price		Contractual Life
	Outstanding at September 30, 2012		32,454,757	$	0.275		0.88
	Granted		0
	Exercised		0		—
	Expired		21,104,757		0.275
	Outstanding at March 31, 2013		4,950,000	$	0.9		1.7
	Exercisable at March 31, 2013		4,950,000	$	0.9		1.7

5BARz_Agreement

5BARz Agreement	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
5BARz Agreement	'
	Note 8 – 5BARz International, Inc. agreements and transactions
	On December 31, 2010, the Company consented to the transfer of three agreements that they had entered into with Dollardex Group Corp. to 5BARz International, Inc. as follows;
	(i)	An “Amended and Restated Master Global Marketing and Distribution Agreement.”
	(ii)	An “Asset Purchase Agreement”
	(iii)	A “Revolving line of credit agreement and security agreement”.
	These agreements provided for the exclusive global marketing and distribution of the 5BARz line of products and related accessories and the acquisition of a 50% ownership interest in the 5BARz intellectual property. In addition, a revolving line of credit facility has been made available to Cellynx.
	On March 29, 2012, the Company and 5BARz International, Inc. entered into an agreement which provided several amendments to the agreement referred to above. As a result of those amendments, the following arrangements between the Companies was established:
	(iv)	5BARz International, Inc. acquired a 60% interest in the patents and trademarks held by Cellynx Group Inc., referred to as the “5BARz™” technology. That interest in the technology was acquired by delivery of 9,000,000 shares of the common stock of 5BArz International Inc., valued at the date of acquisition at $0.20 per share or $1,800,000 USD.  The acquisition agreement clarified that the ownership interest in the intellectual property does represent that proportionate interest in income earned from the intellectual property.
	(v)	5BARz International, Inc. agreed to make available to Cellynx Group, Inc., a revolving line of credit facility in the amount of $2.2 million dollars of which $765,724 has been advanced as of March 31, 2013.  This revolving line of credit facility expires on October 5, 2013.  Under the terms of the line of credit facility, the Company has the right to convert amounts due under the facility into common stock of Cellynx, at a conversion rate which is the lesser of a fixed conversion rate of $0.00015 per share or a variable rate which is calculated at 25% of the average lowest three closing bid prices of the Cellynx Group, Inc. common stock for a period which is ten (10) days prior to the date of conversion.  At March 31, 2012, the Company converted $78,500 of the amount due under the revolving line of credit facility for 350,000,000 shares of the capital stock of Cellynx Group, Inc.  As a result, Cellynx became a consolidated subsidiary of 5Barz International Inc., on March 29, 2012.
	(vi)	Pursuant to the Master Global Marketing and Distribution agreement between 5Barz International Inc. and Cellynx Group, Inc., 5BARz International, Inc. was obligated to pay to Cellynx Group, Inc., a royalty fee amounting to 50% of the Company’s Net Earnings. That fee would be paid on a quarterly basis, payable in cash or immediately available funds and shall be due and payable not later than 45 days following the end of each calendar quarter of the year.  The asset acquisition agreement amendment referred to herein specified that the royalties would be paid in relation to the ownership of the intellectual property.
	During the six months ended March 31, 2013 and 2012 the following transactions have taken place between the Company and 5BARz International Inc.:
	Line of Credit		31-Mar-13			31-Mar-12
	Opening balance – October 1, 2012 & 2011		$	668,844		$	241,038
	Advances			27,290			392,455
	Management fees			90,000			—
	Interest charges			22,107			32,532
	Share conversions			—			(79,500	)
	Closing balance – March 31, 2013 & 2012			808,241			586,525
	Less – discount on convertible			(42,517	)		(126,861	)
	Line of Credit (net) March 31		$	765,724		$	459,664
	At March 31, 2013 5BARz International Inc. held 854,745,971 shares of the Company’s common stock representing a 53% interest based upon the 1,601,498,001 common shares issued and outstanding in the Company at March 31, 2013. At March 31, 2012 5BARz International Inc. held 413,412,638 common shares of the Company representing a 60% interest, based upon the 690,165,000 common shares issued and outstanding in the Company at March 31, 2012.
	At March 31, 2013 and 2012, the Company holds a reciprocal shareholding in 5BARz International Inc. in the amount of 9,000,000 shares representing a 7% equity interest in 5BArz International Inc. based upon the 123,157,887 shares issued and outstanding at that date.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Commitments and Contingencies	'
	Note 9 – Commitments and Contingencies
	Litigation
	The Company, CelLynx Group, Inc was a Defendant in an action brought by Dolphinshire L.P. regarding its office space in Mission Viejo, CA. That action has since been dismissed. Dolphinshire L.P., a California limited partnership v. CelLynx Group, Inc., a Nevada corporation and Does 1-10, Superior Court of California, Orange County, Case No. 00521213. On November 8, 2011, plaintiff brought suit against the Company for unlawful detainer of offices located at 25910 Acero, Suite 370, Mission Viejo, CA 92691 pursuant to a lease agreement, seeking an unspecified amount of damages not to exceed $25,000. The Company has engaged in settlement negotiations with the plaintiff and management expected to settle. CelLynx has since, by agreement, vacated the leased premises and continues to negotiate a payout of past due rent and penalties and has moved the general office to 4014 Calle Isabella, San Clemente, CA 92672. Past due rents and interest have been included in accounts payable at March 31, 2013 and are subject to adjustments based on the outcome of negotiation.
	On August 27, 2012, an action was brought against CelLynx Inc. and Does 1-10, in the Superior Court of California, El Dorado County, Case No. PCL20120700. On August 27, 2012, plaintiff brought suit against the Company for unlawful detainer of offices located at 5047 Robert J Matthews Parkway, El Dorado Hills, CA 95762 pursuant to a lease agreement, seeking damages of $24,699, legal fees of $3,000 and late charges of $2,041. The Company had by agreement, vacated the leased premises and continues to negotiate a payout of past due rent and penalties. Past due rents have been included in accounts payable at March 31, 2012 and are subject to adjustments based on the outcome of negotiation.
	Certain claims for unpaid wages were filed against CelLynx, Inc. Judgments were obtained commencing in August 2011 for back wages by some of its former employees. Some of those claims have been partially paid and others were expected to be paid in the normal course of business or were to be otherwise defended. Those claims have now been incorporated into California Labor Commission awards in favor of those former employees. Those awards total approximately $263,023 depending on interest charges. It is the Company’s intention to pay these amounts when proceeds are available.
	CelLynx Group, Inc. has received a Cease Trading Order from the British Columbia Securities Commission (BCSC) alleging that the Company is in violation of the British Colombia reporting requirements. The BCSC has assumed that since two the Company's former Directors were domiciled in BC that the company is controlled in BC and therefore subject to its reporting requirements. The Company denies that premise and is appealing the issuance of the CTO. On March 31, 2013, the sole Director of the Company is domiciled in the US.
	In addition to the above, the Company may become involved in legal proceedings in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

Subsequent_Events

Subsequent Events	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Subsequent Events	'
	Note 10 – Subsequent Events
	On April 1, 2013, the Company issued 72,000,000 shares upon the conversion of $3,600 due under the terms of a convertible note agreement. The remaining principle balance of that note is $34,500. As provided in note 4(d) above, in December 2012 the Company’s parent, 5BARz International Inc. received a notice of default on notes entered into with the lender. Accordingly all notes to the lender have been recorded at the default amount at March 31, 2013 as the result of a cross default provision in the agreements. The Company has accrued a default penalty of 50% of the note payable as well as default interest at 22% per annum from the date of the default. The Company has the option to pay the amounts due in cash or in shares as defined in the terms of the note agreements.
	On May 1, 2013 the Company amended the articles of Incorporation to increase the number of authorized shares from 2,000,000,000 to 4,450,000,000.
	On May 15, 2013, the Company’s parent, 5BARz International Inc. converted a further $9,375 due under the terms of a convertible line of credit for 375,000,000 common shares.
	On August 28, 2013, the Board of Directors approved a resolution to issue 20,000,000 options to acquire common stock at a strike price of $0.0002 per share for a period of five years to the estate of Mr. Norm Collins, former Director of the Company.
	On August 28, 2013, the Board of Directors approved a resolution to extend the expiration of the 40,000,000 options to former Employees and Directors of the Company from a two (2) year expiration term to a five (5) year expiration, to expire March 7, 2018. The exercise price of the options remain at $0.0002 per share.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended March 31, 2013, are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2013. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on January 15, 2013 for the fiscal year ended September 30, 2012.
	The accompanying consolidated financial statements include the accounts of CelLynx Group, Inc., and its 100% wholly -owned subsidiary, CelLynx, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include impairment analysis for long lived assets, income taxes, litigation and valuation of derivative instruments. Actual results could differ from those estimates.
Intangible Assets	'
	Intangible Assets
	Acquired patents, licensing rights and trademarks are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees, and models and drawings required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated with applications that are not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident increase in the value of the patents are capitalized.
	Capitalized costs for patents are amortized on a straight-line basis over the remaining twenty-year legal life of each patent after the costs have been incurred. Once each patent or trademark is issued, capitalized costs are amortized on a straight-line basis over a period not to exceed 20 years and 10 years, respectively. The licensing right is amortized on a straight-line basis over a period of 10 years. Based on its review, the Company believes that as of March 31, 2013 and September 30, 2012, there was no significant impairment of its intangible assets
Fair Value of Financial Instruments	'
	Fair value of financial instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these instruments.
	Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:
		•	Level 1. Quoted prices in active markets for identical assets or liabilities.
		•	Level 2. Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.
		•	Level 3. Significant unobservable inputs that cannot be corroborated by market data.
	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the assets that are measured at fair value on a recurring basis.
			Consolidated			Quoted Prices in Active Markets for Identical Assets or Liabilities		Quoted Prices for Similar Assets or Liabilities in Active Markets		Significant
			Balance Sheet			(Level 1)		(Level 2)		Unobservable
										Inputs
										(Level 3)
	Derivative Liabilities:
	Conversion option liability		$	2,420,225		$	—	$	—	$	2,420,225
	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:
			31-Mar-13
	Beginning balance – October 1, 2012		$	1,487,568
	Change in fair value of derivative liabilities			992,832
	Write down of derivative liabilities on default of securities			(51,613	)
	Change in accounting treatment of option and warrant liability			(8,562	)
	Ending balance – March 31, 2013		$	2,420,225
	Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivate liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, which reports to the Chief Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department with support from the Company’s consultants and which are approved by the Chief Financial Officer.
	Level 3 financial liabilities consist of the derivative liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.
	As of March 31, 2013 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.
Derivative Instruments	'
	Derivative instruments
	The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging”. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.
Net Loss Per Share	'
	Net loss per share
	The Company reports loss per share in accordance with the ASC Topic 260, “Earnings Per Share.”, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.  In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities were not included in the calculation of loss per common share for the three and six months ended March 31, 2013 or 2012 because their effect would be anti-dilutive.
Stock - Based Compensation	'
	Stock Based Compensation
	The Company reports stock-based compensation under ASC 718 “Compensation – Stock Compensation”. ASC 718 requires all share-based payments to employees, including grants of employee stock options, warrants to be recognized in the consolidated financial statements based on their fair values. The Company accounts for equity instruments issued to non-employees as compensation in accordance with the provisions of ASC 718, which require that each such equity instrument be recorded at its fair value on the measurement date, which is typically the date the services are performed. The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The model includes subjective input assumptions that can materially affect the fair value estimates. The model was developed for use in estimating the fair value of traded options or warrants. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or options granted.
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made in the financial statements at March 31, 2012 and for the three and six months then ended to conform to the March 31, 2013 presentation. The reclassifications had no effect on net loss.
Recent Accounting Pronouncements	'
	Recent accounting pronouncements
	In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment."  This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this guidance did not have a material effect on the condensed consolidated financial statements.
	FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of March 31, 2013 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2013 or 2012, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

Summary_of_Accounting_Policies

Summary of Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2013
Summary Of Accounting Policies Tables	'
Summary of the assetsB that are measured at fair value on a recurring basis.	'
		Consolidated			Quoted Prices in Active Markets for Identical Assets or Liabilities		Quoted Prices for Similar Assets or Liabilities in Active Markets		Significant
		Balance Sheet			(Level 1)		(Level 2)		Unobservable
									Inputs
									(Level 3)
	Derivative Liabilities:
	Conversion option liability	$	2,420,225		$	—	$	—	$	2,420,225
Fair Value of Financial instruments Assets and Liabilities	'
		31-Mar-13
	Beginning balance – October 1, 2012	$	1,487,568
	Change in fair value of derivative liabilities		992,832
	Write down of derivative liabilities on default of securities		(51,613	)
	Change in accounting treatment of option and warrant liability		(8,562	)
	Ending balance – March 31, 2013	$	2,420,225

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2013
Notes to Financial Statements	'
Intangible Assets	'
		31-Mar-13			30-Sep-12
	Patents	$	46,862		$	46,862
	Trademarks		4,995			4,995
	Licensing rights		4,214			4,214
			56,071			56,071
	Accumulated Amortization		(7,597	)		(7,334	)
	Intangibles, net	$	48,473		$	48,737

Promissory_Notes_Tables_USD

Promissory Notes (Tables) (USD $)	6 Months Ended
	Mar. 31, 2013
Promissory Notes Tables Usd	'
Promissory Notes	'
								Converted to Common Stock
	Issue Date		Note Principal	Note		Accrued				Balance			Balance
				Terms		Interest				31-Mar-13			Sept. 30, 2012
	November. 10, 2007	$	262,356	(a)	$	56,583	$	—	$	318,939		$	313,677
	5-Apr-11		50,000	(b)		49,254		—		99,254			56,247
	5-Jan-12		50,000	(c)		36,324		—		86,324			52,498
	24-May-12		37,500	(d)		14,935		14,400		38,035			38,256
	12-Sep-12		12,500	(e)		7,576		—		20,076			12,549
										562,268			473,677
	Accrued interest									(164,672	)		(69,346	)
	Discount on notes									—			(18,869	)
	Notes payable	$	412,356		$	164,672	$	14,400	$	397,956		$	385,463

Options_Tables

Options (Tables)	6 Months Ended
	Mar. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Options and Warrants Exercisable	'
	Options Exercisable
		Options		Exercise price		Weighted average remaining contract life
	Opening – September 30, 2012		6,400,000	$	0.0008		0.4
	Granted		40,000,000		0.0002		2
	Expired		3,000,000		0.0008		0
	Outstanding – March 31, 2013		43,400,000	$	0.00025		1.87

Warrants_Tables

Warrants (Tables)	6 Months Ended
	Mar. 31, 2013
Warrants Tables	'
Warrant Activity	'
		Number of		Weighted Average		Average Remaining
		Warrants		Exercise Price		Contractual Life
	Outstanding at September 30, 2012		32,454,757	$	0.275		0.88
	Granted		0
	Exercised		0		—
	Expired		21,104,757		0.275
	Outstanding at March 31, 2013		4,950,000	$	0.9		1.7
	Exercisable at March 31, 2013		4,950,000	$	0.9		1.7

Organization_Details

Organization (Details)	0 Months Ended		1 Months Ended	0 Months Ended
	1-May-13	7-May-12	Mar. 23, 2012	Nov. 07, 2008
		Common Stock	Common Stock	Seires A Preferred Stock
Common shares authorized	4,450,000,000	2,000,000,000	1,000,000,000	400,000,000
Common shares issued	'	'	'	45,516,034
Converted Series A Preferred Stock	'	'	'	45,516,034

OrganizationCeLlynxCalifornia_

Organization:CeLlynx-California Agreement (Details) (USD $)	0 Months Ended			1 Months Ended
	1-May-13	Aug. 05, 2008		Jul. 24, 2008
		CeLlynx-California Shareholders		CeLlynx-California Shareholders
Common shares authorized	4,450,000,000	'		77,970,956
CeLLynx California common Stock	'	'		61,983,580
Series A preferred stock, issued	'	'		45,516,034	[1]
Common Stock, issued for CelLynx California-Capital Stock	'	'		32,454,922
Net Assets, reverse merger transaction	'	$1,248,748	[2]	'
[1]	The Series A Preferred Stock automatically would convert into common stock on a one-to-one ratio upon the authorized capital stock of the Company being increased to include not less than 150,000,000 shares of common stock.
[2]	Each CelLynx-California shareholder received 1.2579292 shares of stock in the Company for each share of CelLynx- California capital stock.

Organization_Going_Concern_Det

Organization: Going Concern (Details) (USD $)	6 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Jun. 30, 2009
Organization Going Concern Details	'	'	'
Net Loss from operations	($1,454,094)	'	'
Accumulated deficit	-18,650,447	-17,196,353	'
Negative Cash Flows	-26,992	'	'
Accumulated Deficit Develpment Stage	'	'	($10,948,625)

Fair_Value_Details

Fair Value (Details) (USD $)	Mar. 31, 2013
Conversion Option Liability at Fair Value	$2,420,225
Level 3	'
Conversion Option Liability at Fair Value	$2,420,225

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments (Details) (USD $)	6 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Fair Value Of Financial Instruments Details	'	'
Beginning balance-October 1, 2012	$1,487,568	'
Change in fair value of derivative liabilities	992,832	5,595,012
Write down of derivative liabilities on default of securities	-51,613	'
Change in accounting treatment of option and warrant liability	-8,562	'
Ending balance-March 31, 2013	$2,420,225	'

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Mar. 31, 2013	Sep. 30, 2012
Intangible Assets, Gross	$56,071	$56,071
Accumulated amortization	-7,597	-7,334
Intangibles Assets, net	48,473	48,737
Patents	'	'
Intangible Assets, Gross	46,862	49,862
Trademarks	'	'
Intangible Assets, Gross	4,995	4,995
License rights	'	'
Intangible Assets, Gross	$4,214	$4,214

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	6 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 29, 2012
Amortization expense	$263	$528	'
Interest sold in Patents and trademarks	'	'	60.00%
Maximum	'	'	'
Life of amortization	'20 years	'	'
Minimum	'	'	'
Life of amortization	'10 years	'	'

Promissory_Notes_Details

Promissory Notes (Details) (USD $)	6 Months Ended	12 Months Ended
	Mar. 31, 2013	Sep. 30, 2012
Note Principal	$412,356	'
Accrued Interest	164,672	'
Converted to Common Stock	14,400	'
Note Balance	562,268	473,677
Accrued Interest	-164,672	-69,346
Discount on Notes	'	-18,869
Note Balance,net	397,956	685,463
Novmeber 10, 2007	'	'
Issue Date	10-Nov-07	'
Note Principal	262,356	'
Accrued Interest	56,583	'
Note Balance	318,939	313,677
5-Apr-11	'	'
Issue Date	5-Apr-11	'
Note Principal	50,000	'
Accrued Interest	49,254	'
Note Balance	99,254	56,247
5-Jan-12	'	'
Issue Date	5-Jan-12	'
Note Principal	50,000	'
Accrued Interest	36,324	'
Note Balance	86,324	52,498
24-May-12	'	'
Issue Date	24-May-12	'
Note Principal	37,500	'
Accrued Interest	14,935	'
Converted to Common Stock	14,400	'
Note Balance	38,035	38,256
12-Sep-12	'	'
Issue Date	12-Sep-12	'
Note Principal	12,500	'
Accrued Interest	7,576	'
Note Balance	$20,076	$12,459

Promissory_Notes_Details_Narra

Promissory Notes (Details Narrative) (USD $)	0 Months Ended
	Sep. 12, 2012	24-May-12	Jan. 05, 2012	Apr. 05, 2011	Aug. 15, 2006	Aug. 31, 2006
Convertible Notes Payable [Abstract]	'	'	'	'	'	'
Issue Date	12-Sep-12	24-May-12	5-Jan-12	5-Apr-11	15-Aug-06	'
Principal Amount	$12,500	$37,500	$50,000	$50,000	$250,000	$262,356
Date of Maturity	12-Jun-13	7-Feb-13	3-Jul-12	5-Jan-12	'	'
Interest Rate per annum	8.00%	8.00%	8.00%	8.00%	4.00%	'
Note Payable	'	'	$86,324	$99,254	$318,939	'

Stockholders_Equity_Details

Stockholders Equity (Details) (USD $)	3 Months Ended	6 Months Ended
	Dec. 31, 2011	Mar. 31, 2013	Mar. 31, 2012
Stockholders Equity Details	'	'	'
Number of shares issued	33,506,911	144,000,000	'
Principle/Interest Converted	$34,500	$14,400	$52,700

Options_Outstanding_Additional

Options Outstanding Additional(Details) (USD $) (USD $)	6 Months Ended
	Mar. 31, 2013
Options Outstanding [Abstract]	'
Options	6,400,000
Granted	40,000,000
Expired	3,000,000
Options	43,400,000
Weighted Average Exercise Price	$0.00
Granted	$0.00
Expired	$0.00
Weighted Average Exercise Price	$0.00
Weighted Average Remaining Contractual Life	'
Weighted Average Remaining Contractual Life	'0 years 4 months
Granted	'2 years
Weighted Average Remaining Contractual Life	'1 year 8 months 7 days

Warrant_Activity_Details_USD

Warrant Activity (Details) (USD $) (Warrant, USD $)	6 Months Ended
	Mar. 31, 2013
Warrant	'
Warrant Activity	'
Outstanding at September 30, 2012, Number of Warrants	32,454,757
Granted, Number of shares	0
Exercised, Number of shares	0
Expired, Number of shares	21,104,757
Outstanding at March 31, 2013, Number of Warrants	4,950,000
Exercisable at March 31, 2013, Number of Warrants	4,950,000
Weighted Average Exericse Price	'
Outstanding at September 30, 2012,Weighted average exercise price	$0.28
Expired, Weighted average exercise price	$0.28
Outstanding and exercisable at March 31, 2013, Weighted average exercise price	$0.90
Outstanding September 31, 2012, Average Remaining Contractual Life	'0 years 8 months 8 days
Outstanding and Exercisable March 31, 2013, Average Remaining Contractual Life	'1 year 7 months 0 days

Asset_Acquistion_Agreement_Det

Asset Acquistion Agreement (Details) (USD $) (USD $)	1 Months Ended		6 Months Ended
	Mar. 29, 2012		Mar. 31, 2013
Asset Acquistion Agreement Details Usd	'		'
Name of Company	'5 BARz International Inc.		'
Date of Agreement	31-Dec-10		'
Date	29-Mar-12		'
Asset Purchase Agreement	'		'
Interest sold in Patents and trademarks	60.00%		'
Common stock, received for acquisition	9,000,000		'
Price per share	$0.20		'
Proceeds acquisition	$1,800,000		'
Revolving Line of Credit and Security Agreement	'		'
Amount of credit facility	2,200,000		'
Amount of credit facility advanced	'		765,724	[1]
Expiration date of credit facility	'		'10/5/2013
Conversion Rate-per share of 5BARz common stock-Lesser of:	'		'
(2) Variable Conversion Rate-per share	'25%	[2]	'
Amount of credit facility converted to capital stock of Cellynx Group, Inc.	'		78,500
Subsequent conversions	'		$61,200
Amount of Shares of Cellynx Group, Inc. resulting from conversion of credit facility	'		350,000,000
Master Global Marketing and Distribution agreement	'		'
Royalty fee to Cellynx Group, as % of Company's Net Earnings	'50%	[3]	'
[1]	$668,844 is the net amount advanced as of September 30, 2012. In addition, advances in the amount of an additional $139,700
[2]	25% of average lowest three closing bid prices of Cellynx Group, Inc. common stock for a period which is ten (10) days prior to the date of conversion.
[3]	That fee would be paid on a quarterly basis, payable in cash or immediately available funds and shall be due and payable not later than 45 days following the end of each calendar quarter of the year.

Asset_Acquistion_Agreement_Det1

Asset Acquistion Agreement (Details Narrative) (USD $)	6 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Asset Acquistion Agreement Details Narrative	'	'
Opening balance - October 1, 2012 & 2011	$668,844	$241,038
Advances	27,290	392,455
Management fees	90,000	'
Interest charges	22,107	32,532
Share conversions	'	-79,500
Closing balance - March 31, 2013 & 2012	808,241	586,525
Less - discount on convertible	-42,517	-126,861
Line of Credit (net) March 31	$765,724	$459,664

Asset_Acquistion_Agreement_Add

Asset Acquistion Agreement Additional (Details Narrative)	6 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Asset Acquistion Agreement Additional Details Narrative	'	'	'
Shares held by 5BARz	854,745,973	413,412,638	'
Interest	53.00%	60.00%	'
Common stock, Shares issued	1,601,498,001	690,165,000	1,457,498,081
Reciprocal ownership	7.00%	'	'
Shares of 5BARz	123,157,887	'	'

Litigation_Details_USD

Litigation (Details) (USD $) (USD $)	0 Months Ended		1 Months Ended
	Aug. 27, 2012	Nov. 08, 2011	Aug. 31, 2011
Litigation	'	'	'
Description	'Past Due Rent	'Past Due Rent	'Back Wages
Unspecified amount of damages not to exceed	'	'$25,000	'
Back Wages	'	'	$263,023
Judgment	24,699	'	'
Legal Fees	3,000	'	'
Late charges	$2,041	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	3 Months Ended	6 Months Ended
	Dec. 31, 2011	Mar. 31, 2013	Mar. 31, 2012
Common stock issued for conversion of debt	'	14,400	'
Amount converted	$34,500	$14,400	$52,700
Convetible Debt	'	'	'
Common stock issued for conversion of debt	'	72,000,000	'
Amount converted	'	3,600	'
Note payable	'	34,500	'
5BARz International Inc.	'	'	'
Common stock issued for conversion of debt	'	375,000,000	'
Amount converted	'	$9,375	'
Director	'	'	'
Options Issued	'	20,000,000	'
Price of Share	'	$0.00	'
Former Employees and Directors	'	'	'
Options Issued	'	40,000,000	'
Price of Share	'	$0.00	'